Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8658634 | 0.60 | CYP2A6 (0.32) | CYP2A6ALOX12 | |
| SCHEMBL232638 | 0.59 | ACHE (0.46) | — | |
| SCHEMBL35 | 0.57 | CYP2A6 (0.39) | CYP2A6ALOX12 | |
| SCHEMBL597746 | 0.57 | CYP2A6 (0.39) | CYP2A6ALOX12 | |
| SCHEMBL20526418 | 0.55 | CYP2A6 (0.37) | CYP2A6ALOX12 | |
| SCHEMBL20873650 | 0.55 | CYP2A6 (0.37) | CYP2A6ALOX12 | |
| SCHEMBL5894087 | 0.55 | CYP2A6 (0.44) | ATMCYP2A6ALOX12 | |
| SCHEMBL21253156 | 0.54 | CYP2A6 (0.35) | CYP2A6ALOX12 | |
| SCHEMBL24252 | 0.53 | CYP2A6 (0.41) | ATMCYP2A6ALOX12 | |
| Naphthalene SCHEMBL1331142 | 0.53 | CYP2A6 (1.00) | ATMCYP2A6ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1543 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013214-B1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | claimed |
| EP-1660464-B1 | CASPASE INHIBITORS CONTAINING ISOXAZOLINE RING | LG LIFE SCIENCES LTD (KR) | 2015-02-25 | — | — | EP | claimed |
| US-8569505-B2 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-29 | — | — | US | claimed |
| EP-1506166-B1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131712-A1 | METAL HYBRID COMPOSITE CASTING | Rheinisch-Westfälische Technische Hochschule Aachen (DE) | 2011-10-27 | — | — | WO | claimed |
| EP-2013213-B1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-07-27 | — | — | EP | claimed |
| US-20100125140-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2010-05-20 | — | — | US | claimed |
| US-7569561-B2 | 2,4-diaminopyrimidines useful for treating cell proliferation diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | claimed |
| US-7553831-B2 | Beta-secretase inhibitors; inhibiting cleavage of amyloid precursor protein (APP); hydroxy-functional disubstituted amines such as 6-(([[(2S,3S)-4-(3,5-difluorophenyl)-3-((3-[(dipropylamino)carbonyl]benzoyl)amino)-2-hydroxybutyl](ethyl)amino]carbonyl)amino)hexanoic acid | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | claimed |
| US-7544680-B2 | Constrained compounds as CGRP-receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-09 | — | — | US | claimed |
| US-5521194-A | Hindered N-oxide esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-28 | — | — | US | claimed |
| US-5508290-A | Hindered N-oxide esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-16 | — | — | US | claimed |
| US-5508285-A | Hindered N-oxide esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-16 | — | — | US | claimed |
| US-5491231-A | Hindered N-oxide esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-02-13 | — | — | US | claimed |
| EP-0626954-A1 | BENZOCYCLOHEPTENES, BENZOXEPINES AND BENZOTHIEPINES | MERCK PATENT GmbH (DE) | 1994-12-07 | — | — | EP | claimed |
| EP-0584222-A4 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1994-07-06 | — | — | EP | claimed |
| WO-1994013658-A2 | BENZOCYCLOHEPTENES, BENZOXEPINES AND BENZOTHIEPINES | MERCK PATENT GMBH (DE) | 1994-06-23 | — | — | WO | claimed |
| EP-0584222-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. | RHONE POULENC RORER INT (US) | 1994-03-02 | — | — | EP | claimed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | claimed |
| EP-0420069-A2 | Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics | E.R. SQUIBB & SONS, INC. (US) | 1991-04-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125140-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | UTS2R, TRPV1, GPR17 | ATM 3990/4885CYP2A6 1166/4885ALOX12 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.